Condition: FMF · Sponsor: Assistance Publique - Hôpitaux de Paris
To evaluate the efficacy on clinical symptoms in case of FMF attack among FMF patients resistant to Colchicine of * on demand anakinra treatment (100 mg/d from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) associated with daily colchicine. * compared to analgesic associated with daily colchicine in patients refusing continuous anti-IL-1 treatment.
This description comes directly from the study's public registry record.
Léa SAVEY · 0033 1 56 01 67 91 · lea.savey@aphp.fr
Sophie Georgin-Lavialle, MD,PHD · 00 33 1 56 01 74 31 · sophie.georgin-lavialle@aphp.fr
Always discuss trial participation with your own doctor first.
| Service de Médecine interne Hopital Tenon | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06336733